Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan's Tolerance in Patients With Metastatic Triple-Negative Breast Cancer.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: MEDICA SCIENTIA INNOVATION RESEARCH, SL
- Phase: II
- Execution start: 05/12/2022
- End of execution: 31/12/2025
- IP: ISABEL BLANCAS LOPEZ-BARAJAS
